ABSTRACT Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be
relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with …

Angiogenesis and signaling through the RAS/RAF/mitogen-activated protein/extracellular
signal-regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play …

Background Hepatocellular carcinoma (HCC) is the fifth most common malignancy
worldwide. Unresectable disease patients have median survival of few months. There is a …

Raf kinases and vascular endothelial growth factor receptor (VEGFR) and platelet-derived
growth factor receptor (PDGFR) tyrosine kinases are potential molecular targets for …

Abstract Lessons Learned The combination of trametinib and sorafenib has an acceptable
safety profile, albeit at doses lower than approved for monotherapy. Maximum tolerated …

There is limited evidence on the efficacy of lenvatinib in advanced hepatocellular carcinoma
(HCC) patients. Aim of this meta-analysis was to compare lenvatinib and sorafenib as first …

METHODS: The combination of galunisertib and sorafenib (400 mg BID) was tested in
patients with advanced HCC and Child-Pugh A liver function without prior systemic therapy …

Purpose Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-
proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma …

4001 Background: SOR is the only approved agent in uHCC and new options are needed.
LEN, an inhibitor of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor …

Systemic chemotherapy has had a disappointing track record in the management of
advanced hepatocellular carcinoma (HCC). Single‐agent doxorubicin produces a response …